About Us

Scientific Advisory Board

Scientific Advisory Board


Our world-class scientific advisory board helps us identify the most promising new drug targets and navigate through the clinical development process of a new drug as rapidly as possible.

  • Keith T. Flaherty, M.D.
    Keith T. Flaherty, M.D.
    Director, and Chair of the SAB
  • Ross L. Levine, M.D.
    Ross L. Levine, M.D.
  • Ben Ho Park, M.D., Ph.D.
    Ben Ho Park, M.D., Ph.D.
  • David B. Solit, M.D.
    David B. Solit, M.D.
  • Pasi A. Jänne, M.D., Ph.D.
    Pasi A. Jänne, M.D., Ph.D.

Dr. Keith T. Flaherty has served as SAB Chair since company inception, and sits on the board of directors.

Dr. Flaherty is currently Director of Clinical Research and the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School.

Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certification in these specialties.

He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree from Yale University.

Dr. Ross L. Levine is an Associate Attending Physician at Memorial-Sloan Kettering Cancer Center, an Associate Professor of Medicine at Weill Cornell Medical College, and is the Laurence Joseph Dineen Chair in Leukemia Research at MSKCC.

Dr. Levine manages a research lab that is focused on targeted therapies in myeloid malignancies, and is interested in the application of next generation sequencing technology to the practice of medicine in hematologic cancers.

Dr. Levine trained in internal medicine at Massachusetts General Hospital, and in hematology-oncology at the Dana Farber Cancer Institute, earning board certification in these specialties. He received his M.D. from The Johns Hopkins University School of Medicine and his A.B. degree from Harvard College.

Dr. Ben Ho Park is an Attending Physician at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, and is an Associate Professor of Oncology in the Breast Cancer Research Program at Johns Hopkins University.

Dr. Park manages a research lab that is focused on novel targets and mechanisms of drug resistance in breast cancer.

Dr. Park trained in internal medicine and medical oncology at The University of Pennsylvania, earning board certification in these specialties. He received his M.D. and Ph.D. from The University of Pennsylvania, and his A.B. degree from The University of Chicago.

Dr. David Solit is Geoffrey Beene Chair, and Director of both the Center for Molecular Oncology and Developmental Therapeutics at Memorial-Sloan Kettering Cancer Center.

Dr. Solit manages a research lab that is focused on developing cancer therapies that primarily target tyrosine kinase and steroid receptor signaling.

Dr. Solit trained in internal medicine at Barnes Jewish Hospital and in medical oncology at Memorial-Sloan Kettering Cancer Center, earning board certification in these specialties. He received his M.D. and B.A. degree from The University of Pennsylvania.

Dr. Pasi A. Jänne is the Director of the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute, the Scientific co-director of the Belfer Center for Applied Cancer Sciences and a Professor of Medicine at Harvard Medical School.

Dr. Jänne manages a research laboratory focused on developing targeted therapies and understanding mechanisms of acquired drug resistance in lung cancer.

Dr. Jänne trained in internal medicine at the Brigham and Women’s Hospital and in medical oncology at the Dana Farber Cancer Institute earning board certification in these specialties. He received his M.D. and Ph.D. from The University of Pennsylvania and his B.A. degree from Vassar College.